Research ExplorerPublicationsManagement of Patients with Asymptomatic and Symptomatic Car...

Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease

Standard

Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease : Update on Anti-Thrombotic Therapy. / Pastori, Daniele; Eikelboom, John W; Anand, Sonia S; Patel, Manesh Raman; Tanguay, Jean-Francois; Ricco, Jean-Baptiste; Debus, Eike Sebastian; Mazzolai, Lucia; Bauersachs, Rupert; Verhamme, Peter; Bosch, Jackie; Nikol, Sigrid; Nehler, Mark; Aboyans, Victor; Violi, Francesco.

In: THROMB HAEMOSTASIS, Vol. 119, No. 4, 04.2019, p. 576-585.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Pastori, D, Eikelboom, JW, Anand, SS, Patel, MR, Tanguay, J-F, Ricco, J-B, Debus, ES, Mazzolai, L, Bauersachs, R, Verhamme, P, Bosch, J, Nikol, S, Nehler, M, Aboyans, V & Violi, F 2019, 'Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy', THROMB HAEMOSTASIS, vol. 119, no. 4, pp. 576-585. https://doi.org/10.1055/s-0039-1678527

APA

Pastori, D., Eikelboom, J. W., Anand, S. S., Patel, M. R., Tanguay, J-F., Ricco, J-B., Debus, E. S., Mazzolai, L., Bauersachs, R., Verhamme, P., Bosch, J., Nikol, S., Nehler, M., Aboyans, V., & Violi, F. (2019). Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. THROMB HAEMOSTASIS, 119(4), 576-585. https://doi.org/10.1055/s-0039-1678527

Vancouver

Pastori D, Eikelboom JW, Anand SS, Patel MR, Tanguay J-F, Ricco J-B et al. Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. THROMB HAEMOSTASIS. 2019 Apr;119(4):576-585. https://doi.org/10.1055/s-0039-1678527

Bibtex

@article{6b5a6e888ca94192bd3bb336cadc84a7,
title = "Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy",
abstract = "The most common causes of ischaemic stroke are represented by carotid artery atherosclerotic disease (CAAD) and atrial fibrillation. While oral anticoagulants substantially reduce the incidence of thromboembolic stroke (< 1%/year), the rate of ischaemic stroke and other cardiovascular disease events in patients with CAAD remains high, ranging from 8.4 to 18.1 events per 100 patient-years. Similar to any other atherosclerotic disease, anti-thrombotic therapies are proposed for CAAD to reduce stroke and other cardiovascular events. The 2017 European Society of Cardiology (ESC)/European Society for Vascular Surgery (ESVS) guidelines recommend for patients with asymptomatic CAAD ≥60% the use of aspirin 75 to 100 mg once daily or clopidogrel 75 mg once daily at the exception of patient at very high bleeding risk. For patients with symptomatic CAAD ≥50%, the use of aspirin 75 to 100 mg once daily or clopidogrel 75 mg once daily is recommended. New perspectives for anti-thrombotic therapy for the treatment of patients with CAAD come from the novel dual pathway strategy combining a low-dose anticoagulant (i.e. rivaroxaban) and aspirin that may help reduce long-term ischaemic complications in patients with CAAD. This review summarizes current evidence and recommendations for the anti-thrombotic management of patients with symptomatic or asymptomatic CAAD or those undergoing carotid revascularization.",
keywords = "Aged, Anticoagulants/administration & dosage, Aspirin/administration & dosage, Atherosclerosis/diagnosis, Cardiology/methods, Cardiovascular Diseases/complications, Carotid Arteries/pathology, Carotid Artery Diseases/diagnosis, Clopidogrel/therapeutic use, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Revascularization, Platelet Aggregation Inhibitors/therapeutic use, Risk, Rivaroxaban/administration & dosage",
author = "Daniele Pastori and Eikelboom, {John W} and Anand, {Sonia S} and Patel, {Manesh Raman} and Jean-Francois Tanguay and Jean-Baptiste Ricco and Debus, {Eike Sebastian} and Lucia Mazzolai and Rupert Bauersachs and Peter Verhamme and Jackie Bosch and Sigrid Nikol and Mark Nehler and Victor Aboyans and Francesco Violi",
note = "Georg Thieme Verlag KG Stuttgart · New York.",
year = "2019",
month = apr,
doi = "10.1055/s-0039-1678527",
language = "English",
volume = "119",
pages = "576--585",
journal = "THROMB HAEMOSTASIS",
issn = "0340-6245",
publisher = "Schattauer",
number = "4",

}

RIS

TY - JOUR

T1 - Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease

T2 - Update on Anti-Thrombotic Therapy

AU - Pastori, Daniele

AU - Eikelboom, John W

AU - Anand, Sonia S

AU - Patel, Manesh Raman

AU - Tanguay, Jean-Francois

AU - Ricco, Jean-Baptiste

AU - Debus, Eike Sebastian

AU - Mazzolai, Lucia

AU - Bauersachs, Rupert

AU - Verhamme, Peter

AU - Bosch, Jackie

AU - Nikol, Sigrid

AU - Nehler, Mark

AU - Aboyans, Victor

AU - Violi, Francesco

N1 - Georg Thieme Verlag KG Stuttgart · New York.

PY - 2019/4

Y1 - 2019/4

N2 - The most common causes of ischaemic stroke are represented by carotid artery atherosclerotic disease (CAAD) and atrial fibrillation. While oral anticoagulants substantially reduce the incidence of thromboembolic stroke (< 1%/year), the rate of ischaemic stroke and other cardiovascular disease events in patients with CAAD remains high, ranging from 8.4 to 18.1 events per 100 patient-years. Similar to any other atherosclerotic disease, anti-thrombotic therapies are proposed for CAAD to reduce stroke and other cardiovascular events. The 2017 European Society of Cardiology (ESC)/European Society for Vascular Surgery (ESVS) guidelines recommend for patients with asymptomatic CAAD ≥60% the use of aspirin 75 to 100 mg once daily or clopidogrel 75 mg once daily at the exception of patient at very high bleeding risk. For patients with symptomatic CAAD ≥50%, the use of aspirin 75 to 100 mg once daily or clopidogrel 75 mg once daily is recommended. New perspectives for anti-thrombotic therapy for the treatment of patients with CAAD come from the novel dual pathway strategy combining a low-dose anticoagulant (i.e. rivaroxaban) and aspirin that may help reduce long-term ischaemic complications in patients with CAAD. This review summarizes current evidence and recommendations for the anti-thrombotic management of patients with symptomatic or asymptomatic CAAD or those undergoing carotid revascularization.

AB - The most common causes of ischaemic stroke are represented by carotid artery atherosclerotic disease (CAAD) and atrial fibrillation. While oral anticoagulants substantially reduce the incidence of thromboembolic stroke (< 1%/year), the rate of ischaemic stroke and other cardiovascular disease events in patients with CAAD remains high, ranging from 8.4 to 18.1 events per 100 patient-years. Similar to any other atherosclerotic disease, anti-thrombotic therapies are proposed for CAAD to reduce stroke and other cardiovascular events. The 2017 European Society of Cardiology (ESC)/European Society for Vascular Surgery (ESVS) guidelines recommend for patients with asymptomatic CAAD ≥60% the use of aspirin 75 to 100 mg once daily or clopidogrel 75 mg once daily at the exception of patient at very high bleeding risk. For patients with symptomatic CAAD ≥50%, the use of aspirin 75 to 100 mg once daily or clopidogrel 75 mg once daily is recommended. New perspectives for anti-thrombotic therapy for the treatment of patients with CAAD come from the novel dual pathway strategy combining a low-dose anticoagulant (i.e. rivaroxaban) and aspirin that may help reduce long-term ischaemic complications in patients with CAAD. This review summarizes current evidence and recommendations for the anti-thrombotic management of patients with symptomatic or asymptomatic CAAD or those undergoing carotid revascularization.

KW - Aged

KW - Anticoagulants/administration & dosage

KW - Aspirin/administration & dosage

KW - Atherosclerosis/diagnosis

KW - Cardiology/methods

KW - Cardiovascular Diseases/complications

KW - Carotid Arteries/pathology

KW - Carotid Artery Diseases/diagnosis

KW - Clopidogrel/therapeutic use

KW - Female

KW - Hemorrhage

KW - Humans

KW - Male

KW - Middle Aged

KW - Myocardial Revascularization

KW - Platelet Aggregation Inhibitors/therapeutic use

KW - Risk

KW - Rivaroxaban/administration & dosage

U2 - 10.1055/s-0039-1678527

DO - 10.1055/s-0039-1678527

M3 - SCORING: Review article

C2 - 30703812

VL - 119

SP - 576

EP - 585

JO - THROMB HAEMOSTASIS

JF - THROMB HAEMOSTASIS

SN - 0340-6245

IS - 4

ER -